HØRSHOLM, Denmark – June 28, 2019 On September 7, 2017, Boehringer Ingelheim and Gubra announced a collaboration for the development of novel peptide compounds to treat obesity. In June 2019, the first clinical candidate from this collaboration was nominated, which…
INGELHEIM, Germany and HØRSHOLM, Denmark – May 29, 2019 Obesity is a complex disease and leading cause of morbidity and mortality and there are only insufficient treatment options available. New collaboration aims to develop novel peptide poly-agonists for the treatment…
New York and Hørsholm, Denmark, 18 June 2018 JDRF and Gubra today announced a partnership to develop a glucose-responsive insulin (GRI) as a treatment for people with insulin-requiring diabetes, such as type 1 diabetes (T1D). The Gubra approach is based…
INGELHEIM, Germany and HØRSHOLM, Denmark – September 7, 2017 Obesity affects more than half a billion people worldwide and is a leading risk factor for some of the biggest global drivers of morbidity and mortality, such as heart disease, stroke…
Hørsholm, August 30, 2017 Today, Gubra announced the successful conclusion of a research collaboration with Sanofi, focusing on the discovery of novel gastrointestinal peptides that could potentially lead to the development of drugs for the treatment of diabetes and obesity…
June 1, 2016 Today, Gubra announced a change in its executive management team. In order to continue to stay focused on high scientific standards and to accommodate strong growth going forward in both its client base and revenue, Gubra has…
Hørsholm, September 23, 2013 Gubra today announced the launch of a new research collaboration agreement with Sanofi focusing on the discovery of gut peptides in order to identify novel targets suitable for development of peptide-based drugs for treatment of people…